多聚腺苷酸特异性核糖核酸酶突变相关间质性肺疾病的多中心回顾性研究
本研究回顾性分析了31例携带致病性杂合PARN突变的间质性肺疾病患者,中位诊断年龄59岁,74%有吸烟史或纤维化暴露史,最常见表型为特发性肺纤维化(39%)。中位随访32个月,10例死亡、6例肺移植,无移植生存期中位54个月(95%CI 29至无穷),肺功能年下降256 ml/年。
要点
- PARN突变相关ILD以IPF最常见(39%),但表型异质,可见其他ILD亚型。
- 患者肺功能下降中位256 ml/年,无移植生存期中位54个月(95%CI 29至无穷)。
- PARN突变者肺外表现少于TERT或TERC突变者。
核心结论
- PARN突变个体中IPF常见,但也可观察到其他ILD亚型。
- PARN突变相关ILD患者肺外特征较TERT或TERC突变者少见。
研究设计与样本
- 多中心、回顾性、观察性、非干预性研究,纳入OrphaLung网络随访的ILD且携带致病性杂合PARN突变患者。
- 共纳入31例患者,其中29例来自16个家系,2例为散发病例。
主要发现
- ILD诊断中位年龄59岁(范围54至63岁)。
- 23例(74%)有吸烟史和/或纤维化暴露史。
- 最常见诊断為特发性肺纤维化(12例,39%)。
- 3例发现血液学异常,2例发现肝病。
- 全样本用力肺活量中位年下降256 ml/年(范围-363至-148)。
关键数值与推荐
- 21例接受了ILD特异性治疗:糖皮质激素13例、抗纤维化药物11例、免疫抑制剂5例、N-乙酰半胱氨酸2例。
- 中位随访32个月(范围18至66个月),10例死亡,6例接受肺移植。
- 无移植生存期中位54个月(95%CI 29至无穷)。
临床怎么用
- 对ILD患者应关注PARN突变可能,尤其有家族史或符合IPF表型者。
- PARN突变相关ILD患者需监测肺功能下降及评估肺移植时机。
局限性
- 回顾性观察性设计,样本量较小(31例),可能存在选择偏倚。
- 随访时间中位32个月,部分患者随访时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Poly(A)-specific ribonuclease (PARN) mutations have been associated with familial pulmonary fibrosis. This study aims to describe the phenotype of patients with interstitial lung disease (ILD) and heterozygous PARN mutations. METHODS: We performed a retrospective, observational, non-interventional study of patients with an ILD diagnosis and a pathogenic heterozygous PARN mutation followed up in a centre of the OrphaLung network. RESULTS: We included 31 patients (29 from 16 kindreds and two sporadic patients). The median age at ILD diagnosis was 59 years (range 54 to 63). In total, 23 (74%) patients had a smoking history and/or fibrogenic exposure. The pulmonary phenotypes were heterogenous, but the most frequent diagnosis was idiopathic pulmonary fibrosis (n = 12, 39%). Haematological abnormalities were identified in three patients and liver disease in two. In total, 21 patients received a specific treatment for ILD: steroids (n = 13), antifibrotic agents (n = 11), immunosuppressants (n = 5) and N-acetyl cysteine (n = 2). The median forced vital capacity decline for the whole sample was 256 ml/year (range -363 to -148). After a median follow-up of 32 months (range 18 to 66), 10 patients had died and six had undergone lung transplantation. The median transplantation-free survival was 54 months (95% CI 29 to ∞). Extra-pulmonary features were less frequent with PARN mutation than telomerase reverse transcriptase (TERT) or telomerase RNA component (TERC) mutation. CONCLUSION: IPF is common among individuals with PARN mutation, but other ILD subtypes may be observed.
引用
- Philippot Q, Kannengiesser C, Debray MP, et al. Interstitial lung diseases associated with mutations of poly(A)-specific ribonuclease: A multicentre retrospective study. Respirology. 2022. PMID: 34981600. doi:10.1111/resp.14195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。